

Workshop

**Accelerating EU-US business collaboration in health/e-health
Research & Innovation:
Opportunities, Barriers and Best Practices**

Friday, June 20th, 2014, Boston, MA

**Venue: Atlantic Wharf, Waterfront District
Fort Point Room, 2nd Floor
290 Congress Street, Boston, MA**

Workshop Program

08h30-09h00 Welcome registration, coffee & networking

Session 1 – Opening

09h00-09h15 **Opening: Welcome**
European Commission Representative, Workshop Organizers

Input presentation:

- 09h15-09h50 ○ Scene Setting : BILAT USA 2.0 project goal, aim of the workshop (15 min)
Ms Svetlana KLESSOVA, Director, inno TSD, France
- Transatlantic business driven collaborative health research : drivers, barriers and open issues (20 min)
Mr Richard SATCHER, Sr. Business Manager, RTI International, USA

Industrial feedback from US:

- 09h50-10h05 ○ Transatlantic Research, Technological Development and Innovation (RTDI) cooperation of companies: sharing ideas (15 min)
Mr O. Sinan TUMER, Sr. Director, SAP Co-Innovation Lab, USA

Feedback from a European innovation agency

- 10h05-10h20 ○ Evaluation of the EU-US S&T agreement and the need to integrate an innovation dimension (15 min)
Ms Helena ACHESON, Head of Division, MFG Innovation Agency for ICT and Media Baden-Württemberg, Germany

10h20-10h40 Coffee & networking



Session 2 - Opportunities for transatlantic RTDI business cooperation

Horizon 2020 – the European funding programme - and transatlantic collaboration opportunities in RTDI between businesses

- 10h40-11h20
- RTDI collaboration opportunities for businesses - supporting health-related businesses and transatlantic cooperation - through Horizon 2020 (25 min)
 - Q&A (15 min)
- Mr Laurent BOCHEREAU, Head of Unit "Health - Strategy", European Commission, Health Directorate*

US program(s) and transatlantic collaboration opportunities in RTDI between businesses

- 11h20-12h00
- RTDI transatlantic collaboration opportunities for health related businesses – through the Small Business Innovation Research (SBIR) program at the US National Cancer Institute (NCI) (25 min)
 - Q&A (15 min)
- Mr Michael WEINGARTEN, Director at NCI SBIR & STTR Programs, National Institutes of Health (NIH), USA (online presentation)*

12h00-13h00 Lunch & networking

Session 3 – Panel Presentations

Showcases of transatlantic business collaboration (health/ e-health field) in RTDI: Exchange around real-life experience in transatlantic RTDI collaboration of companies and sharing of good practices, barriers and drivers; Q&A

Moderator: Kirsten RIETH, Senior Innovation Advisor RTI International, USA

- 13h00-14h20
- Bigger, More Impactful Research Projects via Transatlantic Collaboration: A Case of a European Company
Dr Engin VRANA, Director of Fundamental Research of Protip SAS, France, and Scientific Coordinator of IMMODGEL R&D Project funded by the European Union
 - Engineering Prowess of Portugal: Innovating, Investing and Inspiring. Kinematix: case study of opportunities and challenges.
Mr Joseph TERNULLO, JD, MPH, President, Kinematix, USA, Inc.
 - EU-US R&D collaboration between companies – challenges, obstacles and possible solutions from several collaboration cases
Dr Elena CHEKHOVA, General Manager, Biotine Consulting Group, USA
 - How the International Trade Administration Can Help Your Company Identify and Capitalize on Overseas Business Opportunities
Matthew Hein, International Trade Specialist, U.S. Department of Commerce, International Trade Administration, Office of Health and Information Technology

Showcases of cluster/facilitator support (health/ e-health field):

Exchange on transatlantic RTDI collaboration of EU and US companies through intermediaries such as clusters; Support needs, inter-clustering; Q&A

14h20-15h40 *Moderator: Ms Helena ACHESON, MFG Innovation Agency for ICT and Media Baden-Württemberg, Germany*

- E-Health Cluster Development in Massachusetts
Mr Laurance STUNTZ, Director, Massachusetts eHealth Institute at MassTech (MeHI)



- The Importance of clusters to drive competition, innovation and prosperity
Ms Sarah Jane MAXTED, Research Manager, Harvard Business School
- Supporting multi-lateral collaboration in international development : examples, strategies, best practices
Mr Loic ROCABOY, Senior Project Manager, ERAI business internationalization agency, Philadelphia
- Boston Life Sciences University Cluster
Mr Vinit NIJHAWAN, Managing Director Technology Development, Boston University

15h40-
16h00

Coffee & networking

Session 4 - Roundtable discussion

Roundtable

- Opportunities, barriers & drivers for transatlantic RTDI collaboration, focus on health/e-health (60 min)
- Exchange around two main questions:
 1. What challenges have you faced while collaborating with EU [or US] companies [partners]? *If necessary, prompt for specifics.*
 2. If you could change anything, what would you change to improve collaboration with EU [or US] businesses?

16h00-
17h00

Moderator: Svetlana KLESSOVA, inno TSD, France

Panelists (clusters and companies):

- Dr Kate TORCHILIN, CEO, Novaseek Research, co-founder and Board member of Mechanical Drugs Inc., USA
- Dr Anatole KLYOSOV, founder emeritus and member of Scientific Advisory Board, Galectin Therapeutics (NASDAQ: GALT), USA
- Mr Maurice BERENGER, CEO of Protip SAS, France
- Mr Stamatis N. ASTRA, Chief Executive Officer, PhotOral Inc., USA
- General audience

Wrap up and end of the Workshop

17h00-
17h15

- Concluding summary, action items identified, next steps (15 min)

Ms Svetlana KLESSOVA, Director, inno TSD

Contact of organizers / for enquiries:

Eva Fadil e.fadil@inno-group.com, Svetlana Klessova s.klessova@inno-group.com



List of speakers, panelists and moderators (in alphabetical order):

- **Ms Helena ACHESON**, [Innovation Agency for Information Technology and Media Baden-Württemberg](#), Head of Division, Stuttgart, Germany
- **Mr Stamatis N. ASTRA**, Chief Executive Officer, PhotOral Inc., USA
- **Mr Maurice BERENGER**, CEO of Protip SAS, France
- **Mr Laurent BOCHEREAU**, [European Commission DG Research & Innovation](#), Head of Unit “Health – Strategy”, Brussels, Belgium
- **Dr Elena CHEKHOVA**, General Manager, Biotine Consulting Group, Boston, MA, USA
- **Mr Matthew Hein**, International Trade Specialist, U.S. Department of Commerce, International Trade Administration, Office of Health and Information Technology, USA
- **Ms Svetlana KLESSOVA**, [inno TSD](#), Director, Sophia Antipolis, France
- **Dr Anatole KLYOSOV**, founder emeritus and member of Scientific Advisory Board, [Galectin Therapeutics](#) (NASDAQ: GALT), USA
- **Ms Sarah Jane MAXTED**, Research Manager, Institute for Strategy and Competitiveness [Harvard Business School](#), USA
- **Mr Vinit NIJHAWAN**, Managing Director Technology Development, Boston University, USA
- **Ms Kirsten RIETH**, [RTI International](#), Senior Innovation Advisor, NC, USA
- **Mr Loic ROCABOY**, [ERAI USA](#) (Entreprise Rhône-Alpes International - Rhone Alpes Business Internationalisation Agency), Project Manager, Philadelphia, PA, USA
- **Mr Richard SATCHER**, [RTI International](#), Senior Business Manager, NC, USA
- **Mr Laurance STUNTZ**, Director, [Massachusetts eHealth Institute at MassTech \(MeHI\)](#), USA
- **Mr Joseph TERNULLO**, JD, MPH, Kinematix, President, USA, Inc.
- **Dr Kate TORCHILIN**, CEO Novaseek Research, a virtual biobank, and co-founder and Board member of Mechanical Drugs Inc., USA
- **Mr O. Sinan TUMER**, [SAP Co-Innovation Lab](#), Sr. Director, Newtown Square, PA, USA
- **Dr Engin VRANA**, [Protip SAS](#), Director of Fundamental Research, Strasbourg, France (European company involved in the R&D European-funded project “IMMODGEL”, in collaboration with The Brigham and Women's Hospital, Boston)
- **Mr Michael WEINGARTEN**, [NIH](#), Director at National Cancer Institute: Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) Programs of the National Institutes of Health (NIH) Maryland, USA

Short Bios (in alphabetical order):

Ms Helena ACHESON has a thirty year career spanning a diverse range of large national and regional economic- and enterprise development organizations, both private and public, mainly in Ireland and more recently in Germany. She regularly contributes to EU policy development as Chair or Expert and, is a Board member of the Alberta Research & Innovation Authority, Canada and CTVR, the national Telecommunications Research Centre in Ireland. She worked in Forfás www.forfas.ie since its establishment in 1994 until Sept 2010. There she managed Ireland's first national Technology Foresight exercise (1998/1999), the work of the National Competitiveness Council, the Irish Council for Science, Technology and Innovation, DISCOVER - the national Science Awareness Programme and contributed to the development of the Irish National Science & Technology Strategy 2006-2013. Prior to Forfás, Helena was the Technology Transfer Manager in the Enterprise Ireland East Region Office and was the Project Manager in the Office for Science & Technology at the Ministry for Enterprise, Trade and Employment for SERTEC, a regional S&T infrastructural investment programme. Before moving into the public sector, Helena worked for over six years with the national industry representative organisation, Irish Business Employers Confederation, IBEC.



Since February 2012, Helena has been working as Head of Division in Stuttgart for MFG, the regional innovation agency for ICT and Media.

Mr Stamatis N. ASTRA is the founder and CEO of Boston-based PhotOral,™ a life science startup focused on commercializing photo-medicine technology for the oral care market. PhotOral has entered into a commercial partnership with a global health care company to bring to market its first product. Astra's early career brimmed with startup experience ranging from 'dot-com' VOIP software firm, TeleGea, where he built a global customer network from Tokyo to Brazil as Vice President of Technology – to more recently, the online identity theft solutions-based startup identityTruth, which he co-founded and later sold. Astra served as the CEO of a multinational manufacturer listed on Canada Stock Exchange before returning to the startup world. Astra holds a BS in Economics magna cum laude as well as an MBA and MS in Communications Management—also with honors and all from Boston University. Astra is Chairman of Development for Boston University's Arion Journal of Humanities and The Classics, and hosts his talk show on WNTN-1550 AM for a Greek-American audience in Boston. A staunch community service advocate, Astra lends his business expertise to numerous organizations and charities in New England and in Athens, Greece.

Mr Maurice BERENGER, CEO of Protip SAS (France), has a degree in Physics and a background in state-of-the-art medical technology and he has been active in management in the Med Tech sector for more than 20 years (Guidant, MedPole, MedSys, etc.). He joined Protip in 2009 and has been involved with the first round of fundraising of the company post-creation. He is an expert in business planning and management; after directing several start-up companies over the years. Currently he is also a board member of two other biomedical companies; DefyMed and EndoTools Therapeutics.

Mr Laurent BOCHEREAU is responsible for the "Strategy" Unit within the Health Directorate of the European Commission's Directorate General for Research and Innovation. He gained a Laureate from the Ecole Polytechnique in Paris, a Master's degree from the University of California and a PhD from the University of Paris VI. After spending several years working as a research project leader at IRSTEA, he served two years in the French Ministry for Research. He joined the European Commission in 1995 where he worked several years as assistant to the Director for Life Sciences and then as Head of Unit with responsibilities for agriculture, forestry, agro-industry and food safety research. From 2007 to 2010, he was the Head of the "Science, Technology and Education" Section at the Delegation of the European Union in Washington DC and from 2010 to 2013, Head of Unit for "International Cooperation Policy" in the European Commission's Directorate General for Research and Innovation.

Dr Elena CHEKHOVA is a general manager of Biotine Consulting Group, a life science consultancy providing business development and project management services to life science companies in the US and internationally. Dr. Chekhova is also a strategic adviser to LayBio, a drug delivery company out of MIT focused on development of novel drug delivery solutions to unmet medical needs in wound care, orthopedics and other therapeutic areas. Among Biotine clients were Galectin Therapeutics, Zafgen, Link Medicine, Tokai, Fresenius, Aphios, ChemDiv, Accellient, Stealth Peptides, Isloo7, etc. Prior to founding Biotine, Elena served as Vice President of Business development at Chiral Quest, a manufacturing and technology start-up with offices in NJ and China. Previously Elena held positions in business development and project management at Pro-Pharmaceuticals, deCODE and Regis technologies. Earlier in her career, she worked for McKinsey and Bertelsmann AG in Germany. Elena completed her Ph.D in Chemical Engineering at MIT and University of Dortmund in Germany. She was a 2012 Fellow in the Startup Leadership Program in Boston.

Mr Matthew Hein is an International Trade Specialist in the Office of Health and Information Technology (OHIT), part of the Industry and Analysis division of the International Trade Administration (ITA) in the U.S. Department of Commerce. Since September 2005, he has followed medical device issues in Southeast Asian



countries (excluding China and Japan), and also tracked domestic and international developments in the Health Information Technology (Health IT) sector. In October 2010, he completed an 18-month set of courses and work assignments to graduate from the Commerce Department's Executive Leadership Development Program. Prior to joining ITA, Mr. Hein worked as a statistician/economist for two trade associations, the Beer Institute (1994-2004) and the National Automobile Dealers Association (2004-2005). Mr. Hein received his MBA from the University of Maryland, College Park in 1988.

Ms Svetlana KLESSOVA, M.Sc, is Director and senior innovation consultant at inno TSD, Sophia Antipolis, France (established in 1986), the French subsidiary of the inno group, an innovation management consulting company with over 60 staff serving research institutions, businesses, policy institutions and development agencies in Europe and abroad. She has 20+ years of experience in innovation policies, technology commercialization, entrepreneurship, international R&D & innovation cooperation. She is an expert for UNIDO – United Nations Industrial Development Organisation. Svetlana has been leader or senior consultant on 50+ science, technology and innovation-related projects with R&D partners and industrial partners all over the world. She coordinates Health-2-Market initiative funded by the European Commission / Health Directorate, that aims at developing the Health researchers' entrepreneurial skills and knowledge to support the market exploitation of their research results, and provides training in IPR and asset management, entrepreneurship and business planning, launch of a successful start-up and knowledge transfer, etc.

Dr Anatole KLYOSOV, Ph.D., D.Sc., is founder emeritus and member of Scientific Advisory Board, Galectin Therapeutics (NASDAQ: GALT), a biotechnology company applying its leadership in galectin science and drug development to create new therapies for fibrotic disease and cancer. He is a co-inventor of the patented technology. From 1996 to 2000, he was vice president of research and development for Kadant Composites, Inc., a subsidiary of Kadant, Inc. (NYSE: KAI), where he directed a laboratory specializing in biochemistry, microbiology and polymer engineering. From 1990 to 1998, Dr. Klyosov was visiting professor of biochemistry at the Center for Biochemical and Biophysical Sciences at Harvard Medical School. Dr. Klyosov was elected to the World Academy of Art and Science. He holds over 20 patents, has published more than 250 peer-reviewed articles in scientific journals, and edited two books, *Carbohydrates in Drug Design* and *Galectins*.

Ms Sarah Jane MAXTED is a Research Manager at the Institute for Strategy and Competitiveness (ISC), Harvard Business School, focusing on clusters and regional economic growth. The ISC, run by Dr. Michael Porter, focuses on the study of competition and its implications for company strategy across nations, regions, cities, and broader society as well as developing new theory, and disseminating ideas widely to stakeholders in both the public and private sector. She manages the U.S. Cluster Mapping Project, a national economic initiative that aims to strengthen U.S. competitiveness by understanding the economic performance of clusters and regions across the U.S. The project provides an interactive website for user-driven, visual data on clusters and regions across the U.S. It benchmarks the economic performance of individual clusters and regional business environments, and also provides a community for organizations, policymakers, and researchers to share and discuss best practices in economic development, policy, and innovation. Most recently Sarah Jane worked for Deloitte Consulting LLP with a focus industrial partnerships, innovative financing, and both research and development, and economic development. She has a diverse background in energy ranging from energy policy to clean energy technology commercialization to developing prizes and challenges. She developed and ran the U.S. Department of Energy (DOE) National Clean Energy Business Plan Competition where hundreds of start-up companies have formed. While at the DOE she focused on regional clean energy ecosystem development with an emphasis on accelerating technology transfer from the 17 DOE National Laboratories. She has worked for both the private and public sector, and Federal and state levels, over her career including the DOE for both the Secretary of Energy and the Energy Efficiency and Renewable Energy Program Office, CGI (consulting firm) in their oil and gas sector as well as for former Senator John F. Kerry. Originally from Colorado, Ms. Maxted



went to Duke University where she double majored in Energy Policy and Cultural Anthropology. She has also spent significant time in Washington, D.C. working for President Obama's Administration.

Mr Vinit NIJHAWAN is Managing Director, Office of Technology Development, and Executive-in-Residence at ITEC (Institute of Technology, Entrepreneurship & Commercialization) at Boston University. Vinit also teaches MBA courses on Entrepreneurship at BU, over 225 students have taken his courses. Vinit has over 30 years experience building five startups: as CEO of three, five were acquired. Vinit was Venture Partner at Key Venture Partners and over two years sourced over 200 deals and made one investment that was acquired for \$430M. Vinit is an advisor and board member to several technology startups and was a Mass High Tech All-Star in 2005. Vinit has participated in over 150 panel discussions and paper presentations, and is a Board Member of Mass Ventures, an early stage, quasi-public Massachusetts venture capital firm and a co-founder of EdTech Accelerator LearnLaunchX. Vinit earned a B.A.Sc in electrical engineering from the University of Waterloo in Ontario, Canada.

Ms Kirsten RIETH, MBA, BSME, is a Senior Innovation Advisor at RTI International. RTI is a not-for-profit research organization with 3700 employees worldwide working in the areas of health, international development, social science, and technology development. Kirsten works at the intersection of technology and business in RTI's Innovation Advisors consultancy, supporting businesses, universities, federal laboratories, and government agencies find, commercialize, and apply technologies for economic benefit. Through this work Kirsten facilitates collaborations and partnerships among organizations for mutual benefit, and studies adoption issues in order to plan for technology commercialization and market entry strategies. She also manages RTI's membership in the US-EU Match consortium, a bridge to the Enterprise Europe Network's more than 600 EU members.

Mr Loic ROCABOY is a Senior Project Manager at ERAI USA, the trade development agency of the Rhône-Alpes region in France. Among his main responsibilities is the support to French companies to export their products, services and expertise in the US. Additionally, he is in charge of the Biotechnologies and Health Sector and has been involved in many collaboration projects between European and American organizations, with a focus on clustering and partnering between research institutions.

Mr Rick SATCHER, MS, MBA is a Senior Business Manager at RTI International, a non-profit research institute in Research Triangle Park, NC. He has 15 years of broad experience in strategic planning, business development, finance, market research, and project management. Mr. Satcher's key area of interest is in building collaborative partnerships between the public and private sectors to develop new therapeutics and diagnostics that address unmet health needs. He has worked with corporate, government, and academic clients to address barriers to collaborative health research and recently completed a study of EU's Innovative Medicines Initiative. Prior to joining RTI, Mr. Satcher directed all sales and marketing activities for Fulcrum Pharma Developments, a drug development consulting company that specializes in strategy and management of lead to proof-of-concept development programs. As a consultant at BioAbility, LLC, Mr. Satcher prepared life science-related business studies, strategic plans, and market analyses of new therapeutics and performed technology and market assessments for intellectual property developed at major U.S. universities.

Mr Laurance STUNTZ is the Director of the Massachusetts eHealth Institute, the Commonwealth's entity for health care innovation, technology, and competitiveness and is responsible for advancing the dissemination of health information technology throughout Massachusetts, including the deployment of electronic health records systems in all health care provider settings and connecting them through the statewide health information exchange, the Mass HIway. For more information, please visit www.mehi.masstech.org. At the Massachusetts eHealth Institute, Mr. Stuntz is driving forward the Commonwealth's initiatives to digitize healthcare data across the state, get that data moving between providers, and find new uses for the data to



improve the overall quality of the health care delivered in the state. He is particularly interested in ensuring that patients have access to their data and become an active and engaged participant in managing their health. Prior to joining the eHealth Institute, Mr. Stuntz worked for private industry and has over 20 years of experience in healthcare information technology product development, systems integration and management consulting. Much of this work was focused on collaboration and exchange of information among all types of healthcare organizations. He was the Senior Vice President responsible for product development for NaviNet and was a Partner at Computer Sciences Corporation (CSC) with responsibility for CSC's Collaborative Communities solution area. He has led, worked on and contributed to some of the most significant health information exchange efforts in the United States, including the New England Healthcare Exchange Network (NEHEN), MA-SHARE ePrescribing and Clinical Exchanges, and the CAQH Committee on Operating Rules for Information Exchange (CORE) project.

Mr Joseph TERNULLO, JD, MPH, is the US president of Kinematix. Prior to joining Kinematix, Joe was associate director of Partners HealthCare's Center for Connected Health. He has served on the US Department of Health and Human Services' American Health Information Community Workgroup and the US Commerce Department's International Trade Advisory Committee, co-founded Continua Health Alliance and served on several boards. Joe holds degrees from Boston College, Bentley University, Boston University School of Law and Harvard School of Public Health.

Dr Kate TORCHILIN is CEO of Novaseek Research, a virtual biobank serving the needs of the hospitals, pharmaceutical and clinical research industries. Dr. Torchilin is also co-founder and Board member of Mechanical Drugs Inc., innovative oncology company developing technology for efficient diagnosis and treatment of resistant and lethal cancers. Previously, Dr. Torchilin served as Vice President and General Manager, Connected Health, and Vice President of Women's Health global business at Alere Inc, the leading point of care diagnostics company. Prior to that, Dr. Torchilin was CEO of Biocell Center, stem cell tissue bank and technology company. Earlier in her career, Dr. Torchilin held various management positions at Thermo Fisher Scientific, and also worked in a technology licensing role at Beth Israel Deaconess Medical Center, a Harvard Medical School teaching hospital. Dr. Torchilin has an MBA from Harvard Business School, PhD in Biochemistry from Tufts University and BS in Chemistry from Moscow State University, Russia.

Mr O. Sinan TUMER is the Senior Director of SAP Co-Innovation Lab in the East Coast region of USA. He is responsible for establishing an open innovation process by harnessing SAP's partner ecosystem to deliver innovative business solutions to SAP's customers. Previously he was responsible for managing international research policies at SAP Research with special focus on Research & Innovation deployment and early adoption programs of the US and EU governments. During his long career at SAP America, he held various management positions like Director of Operations at SAP Research, Consulting Director of the US North East region and Software Partner Alliance Director. Prior to joining SAP, he had held various IT management positions at various Consumer Goods companies and Systems Integration consulting positions at Andersen Consulting and Price Waterhouse. Sinan has a Master degree in Systems Engineering and a Master of Science in Computer Sciences, both from Georgia Institute of Technology.

Dr Engin VRANA, Protip SAS, Director of Fundamental Research, Strasbourg, France, obtained his PhD in 2009 at Dublin City University as a Marie Curie ESR fellow. His major research interests are titanium implants, tissue engineering, cell encapsulation and cell biomaterials interactions. He has published 26 articles in peer-reviewed academic journals, 4 book chapters and holds 2 European patents. His awards include Parlar Foundation Thesis of the Year (2006), ESB Translational Research award (2011) and 2nd Aegean R&D Patent competition 1st place award (2012). He is Scientific Coordinator of IMMODGEL, "Local Immunomodulation around implants by innovative auxiliary hydrogel-based systems encapsulating autologous and phenotype controlled macrophages", an R&D collaborative project funded by the European Union under the 7th Framework Programme for Research, Technological Development and Demonstration (project duration



BILAT USA 2.0

10/2013 – 09/2017, project budget 8.1 mln eur, including 5.8 mln eur EC funding, the consortium partners include US-based organization, Brigham and Women's Hospital).

Mr Michael WEINGARTEN is the Director for the Small Business Innovation Research (SBIR) Development Center at the National Cancer Institute (NCI). In this role, Mr. Weingarten leads a team of 9 Program Directors who manage all aspects of the NCI SBIR & STTR Programs including a portfolio of over \$110M in grants and contracts annually. The SBIR & STTR programs are NCI's engine of innovation for developing and commercializing novel technologies and products to prevent, diagnose, and treat cancer. Under Mr. Weingarten's leadership and direction, the NCI SBIR Development Center has launched a range of new programs to facilitate the success of small businesses in the cancer space, including the SBIR Phase II Bridge Award, which more than triples the amount of funding available to applicants through the NCI SBIR Program. NCI SBIR has also launched an annual investor forum where potential investors can get a first look at some of the most promising NCI SBIR companies that are developing the next generation of cancer therapeutic, diagnostic, or imaging technologies.

About BILAT USA 2.0:

[BILAT USA 2.0](#) is a project funded by the European Commission under FP7 (GA N° 312081). BILAT USA 2.0 aims at enhancing Science, Technology and Innovation collaboration between the EU and the US.

About the co-organizers:

[inno TSD](#), an innovation management consultancy serving businesses, research institutions, and policy makers in Europe and abroad to create optimal framework conditions for innovation.

[RTI International](#), a non-for-profit research organization with 3700 employees worldwide working in the areas of health, international development, social science, and technology development.

[Diplomacy Matters Institute](#), a 501(c)(3) nonprofit organization dedicated to generating new platforms for meaningful dialogue among diplomats, government officials, academic experts, and business leaders

